Research programme: stem cell therapies - ReNeuron

Drug Profile

Research programme: stem cell therapies - ReNeuron

Alternative Names: ReN 002; ReN 003

Latest Information Update: 16 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Harvard Medical School; ReNeuron
  • Developer ReNeuron; Schepens Eye Research Institute
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements; Pancreatic beta cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Retinal disorders; Retinitis pigmentosa; Type 1 diabetes mellitus

Most Recent Events

  • 16 Jun 2015 ReNeuron plans a phase I/IIa trial for Retinitis pigmentosa in USA (NCT02464436)
  • 23 Apr 2008 Pharmacodynamics data from a preclinical trial in Retinal disease released by ReNeuron
  • 04 Apr 2008 Preclinical development is ongoing for Retinal disorders and Type-1 diabetes mellitus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top